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ABSTRACT 26 
Background & aims: There is convincing clinical evidence to suggest that flavanol-containing 27 
foods/beverages are capable of inducing improvements in human vascular function.  28 
However, whilst pure (-)-epicatechin has been tested for efficacy, a full dose-dependency has 29 
yet to be established, particularly at doses below 1 mg kg-1 BW. The current study examined 30 
the dose-dependent effects of pure (-)-epicatechin on human vascular function with concurrent 31 
measurement of plasma (-)-epicatechin metabolites and levels of circulating nitrite and nitrate 32 
species, NOx.  33 
 34 
Methods: An acute, double-blind, placebo-controlled, crossover intervention trial was 35 
conducted in 20 healthy males with 4 treatment arms: water-based (-)-epicatechin (0.1, 0.5 36 
and 1.0 mg kg-1 BW) and a water only as control.  Vascular function was assessed by flow-37 
mediated dilatation (FMD), laser Doppler imaging with iontophoresis (LDI) and peripheral 38 
blood pressure (BP) at baseline, 1, 2, 4 and 6 hours post-intervention.  Plasma analysis of 39 
epicatechin metabolites was conducted by LC-MS and circulating plasma of nitrite and nitrate 40 
species were performed using an HPLC-based system (ENO-30). The study was registered 41 
with the National Institutes of Health (NIH)-randomized trial records (NCT02292342). 42 
 43 
Results: Significant increases in % FMD were found to occur at 1 and 2 h following intake of 44 
1 mg kg-1 BW , and at 2 h for the 0.5 mg kg-1 BW intake.  There were no significant changes 45 
in LDI or BP at any time-points or intake levels.  Increases in FMD over the 6 h timeframe 46 
were closely paralleled by the appearance of total plasma (-)-epicatechin metabolites.  Dose-47 
related but non-significant changes in circulating NOx were also observed. 48 
 49 
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Conclusions: Our data add further evidence that (-)-epicatechin is a causal vasoactive 50 
molecule within flavanol-containing foods/beverages. In addition, we show for the first time 51 
that intake levels as low as 0.5 mg kg-1 BW are capable of inducing acute improvements in 52 
vascular function (FMD) in healthy volunteers.  53 
 54 
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1. Introduction 72 
Cocoa is a rich source of flavanols which has been extensively investigated for its impact on 73 
vascular health at a number of levels, including at the population level, in a growing number 74 
of human intervention trials [1-6].  Recent dietary interventions in humans have substantiated 75 
epidemiological data on an inverse relationship between flavanol cocoa intake and the risk of 76 
cardiovascular diseases. Various flavanol-mediated bioactivities after cocoa consumption 77 
have enhance the endothelial function and vascular tone of “at risk” and “healthy” individuals 78 
by means of increasing flow-mediated dilation (FMD) of the brachial artery, lowering arterial 79 
blood pressure or increasing the circulating pool of nitric oxide [7-16]. 80 
 81 
Despite these datasets, a full understanding of the causality between components of 82 
cocoa and human vasoactivity remains to be established. The reasons for these shortcomings 83 
are, at least in part, based on the fact that food matrices contain a multitude of phytochemical 84 
constituents of which an unknown number may exert physiological effects.  85 
 86 
The main flavanols of cocoa are specially epicatechin, catechin and their oligomeric 87 
derivatives known as procyanidins. However, the chiral nature of monomeric flavanols should 88 
be noted since the bioactivity of flavanols is significantly influenced by the (+)/(-) 89 
stereochemical configuration. Among them, (-)-epicatechin is thought to be the most likely 90 
physiologically active compound responsible for the vascular health benefits associated with 91 
cocoa since the oral administration of (-)-epicatechin produced a vascular response nearly six 92 
times higher than that of (-)-catechin [17]. Therefore, subsequent human intervention trials 93 
were focused on the elucidation of the casual vascular effects after human ingestion of pure (-94 
)-epicatechin. 95 
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From an acute study conducted with healthy male adults emanated that the oral 96 
administration of chemically pure (-)-epicatechin closely emulated acute vascular effects of 97 
flavonol rich cocoa [18]. All individuals had significantly increased the peripheral arterial 98 
tonometry index and the FMD at two hours after (-)-epicatechin ingestion at doses of 1 or 2 99 
mg kg-1 of body weight, potentially though induction of an NO-mediated pathway [18]. 100 
Controversially, other controlled, double-masked, crossover study in humans concluded that 101 
although (-)-epicatechin intake increased low-mediated arterial dilation, this outcome did not 102 
reach statistical significance disproving the health benefits of (-)-epicatechin [19]. Some 103 
authors disproved this statement due to the heterogeneity in vascular status of the study 104 
population, especially considering the small total number of participants of whom 22 % would 105 
be considered as hypertensive [20]. This fact should have not overlooked and unappreciated 106 
due to its impact on outcomes and final interpretations which could mask meaningful 107 
conclusions. Therefore, due to the controversy regarding to the physiological effect of (-)-108 
epicatechin, further research including reliable clinical trials with appropriate population 109 
should be conducted to address its potential health benefits. On the other hand, the minimum 110 
effective dose of (-)-epicatechin to induce significant physiological effects is another 111 
important remaining challenge which should be addressed. 112 
 113 
For that reasons, the current trial investigates the impact of 3 intake levels of pure (-)-114 
epicatechin, 0.1, 0.5 and 1.0 mg kg-1 on human vascular function over a 6 h period, primarily 115 
by assessment of flow-mediated dilatation (FMD). The study was designed to objectively 116 
elucidate the minimum effective dose and timeframe at which improvements in FMD are 117 
observed in response to pure (-)-epicatechin intake.   118 
 119 
 120 
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2. VOLUNTEERS AND METHODS 121 
2.1.Clinical trial ethics 122 
The clinical study was conducted in line with the guidelines in the Declaration of Helsinki and 123 
study protocols were approved by the University of Reading Research Ethics Committee, UK 124 
(reference: 11/31) and Kantonale Ethikkommission Bern, Switzerland (reference 039/12). The 125 
trial was registered with the National Institute of Health (NIH) records on ClinicalTrials.gov 126 
website (NCT02292342). 127 
 128 
2.2. Volunteers and Intervention  129 
A total of 20 individuals were recruited (Figure 1A) to voluntarily participate in the trial via 130 
poster advertisement at the University of Reading and surrounding area.  Volunteers were 131 
assessed for health status using a standard health & lifestyle questionnaire and recruited on the 132 
basis of their compliance to the inclusion and exclusion criteria for the trial. Inclusion criteria: 133 
signed consent form, male aged 18-40 years, non-smoker, absence of metabolic (e.g. diabetes) 134 
and cardiovascular-related disorders (no pre-existing CVD and/or previous incidents), normal 135 
blood pressure (>150/90 mm Hg) and haematological parameters (liver enzymes, 136 
heamoglobin, hematocrit and leukocyte counts).  Exclusion criteria: individuals who were or 137 
had administered medication (including anti-inflammatory, antibiotics or blood pressure 138 
lowering medication) or nutritional supplements (including vitamin, mineral and fish oil 139 
supplements) with 2 months prior to the trial start date. Vegetarians/vegans and individuals 140 
with an extreme exercise routine were also excluded on the basis of their regular diet and 141 
activity.  Throughout the trial period (including during washout), volunteers were asked to 142 
maintain their normal diet, activity and fluid intake except for 24 h before and during the 143 
study day, where volunteers were asked to restrict their diet to low polyphenol-containing 144 
foods, including fruit, vegetables, cocoa, chocolate, tea and wine; intake of nitrate-rich 145 
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foods/beverages such as leafy green vegetables, beetroot, processed meat and tap water (rich 146 
source of nitrate in UK).  They were also asked to restrict vigorous exercise  to > 20 min per 147 
day and the consumption of alcohol to > 168 g alcohol per week (14 arbitrary units in UK).  148 
 149 
2.3. Interventions: Pure (-)-epicatechin test drinks 150 
To investigate the dose-dependent activity of pure (-)-epicatechin relative to vascular 151 
function in healthy males at and below 1 mg kg-1 BW, pure, food-grade (-)-epicatechin (EC) 152 
(Yancui Import & Export Corporation Limited, Shanghai, China). Analysis of EC was 153 
performed at NRC (Lausanne, Switzerland) to ascertain its purity and safety for use in clinical 154 
human intervention trials.  (-)-Epicatechin was stored at -80 º till use and test interventions 155 
were prepared at 3 doses of pure EC (1.0, 0.5, and 0.1 mg kg-1 EC) by dissolution in low-156 
nitrate drinking water at room temperature (3 mL kg-1 of BW) [18].  Volunteers were 157 
randomly allocated to each intake level of pure EC or the control treatment (water only) via a 158 
block randomisation method (A-D).  159 
 160 
2.4. Study design 161 
The trial was a randomised, double-blind, placebo-controlled, crossover intervention 162 
with 4 treatment arms in which volunteers consumed a water-based test drink containing 0.1, 163 
0.5 and 1.0 mg/kg BW of (-)-epicatechin or a control drink containing water only.  All 164 
volunteers on the study were recruited under the supervision of a qualified research nurse, 165 
alongside trained researchers. All responsible parties involved in conduction of the trial and 166 
assessment of the study outcomes were blinded to treatment allocation, as well as the 167 
participating volunteers. In compliance with the study protocol, volunteers were required to 168 
attend the Hugh Sinclair Unit of Human Nutrition on 4 separate occasions to assess each 169 
treatment during a 6 h time course where they were randomised to a treatment schedule via a 170 
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block randomisation system (Figure 1B). 24 h prior to a study day visit, volunteers were asked 171 
to follow a low-polyphenol/nitrate diet in which consumption of specific foods and beverages 172 
were restricted and were instructed not to consume alcohol or partake in strenuous physical 173 
activity during this restrictive period.  A low-fat, low-polyphenol meal was also provided to 174 
all volunteers the evening prior to each visit and were asked to consume this before 20:00 in 175 
order to allow for a 12 h overnight fast. 176 
 177 
On arrival to the Nutrition Unit the weight of each volunteer was recorded to 178 
determine the precise amount (mg) of (-)-epicatechin they will receive relative to the arm of 179 
the trial they were currently assigned to.  Volunteers were cannulated (left arm) by a qualified 180 
research nurse and blood and urine samples were collected in the fasted state.  Following a 30 181 
min period of inactivity under temperature-controlled conditions 21ºC, baseline FMD 182 
measurements of the brachial artery (primary outcome), peripheral blood pressure (systolic 183 
and diastolic BP), laser Doppler imaging with iontophoresis to measure cutaneous perfusion 184 
of acetylcholine and sodium nitroprusside (LDI) and plasma nitrite/nitrate and epicatechin 185 
metabolites analyses were carried out.  Following baseline measurements, volunteers were 186 
orally administered test or control interventions (30 sec max).  Additional vascular measures 187 
including FMD and BP were conducted at 1, 2, 4 and 6 hours post intake and LDI at 2, 4 and 188 
6 hours after (-)-epicatechin ingestion. Blood samples were collected at 1, 2, 4 and 6 hours 189 
after consumption and urine at 2 and 6 h during the visit and for a total of 24 h.  Volunteers 190 
received a small low-fat, low-flavonoid containing lunch 4.5 h post intervention.  All 191 
volunteers followed a 14-day washout period between study days, where they were asked to 192 
adhere to their normal diet and exercise regime.  193 
 194 
2.5. Vascular measurements 195 
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2.5.1. Flow-mediated dilatation 196 
 FMD of the brachial artery was the primary end point measure of the study measured 197 
following standard guidelines [21] using an ALT Ultrasound HDI5000 system (ATL 198 
Ultrasound, UK), with a semi-automated computerized analysis system (Brachial Analyzer, 199 
Medical Imaging Applications-llc, IL, US). After 30 min supine rest in a quiet, air-200 
conditioned room, the brachial artery was imaged longitudinally at 2-10 cm proximal to the 201 
antecubital fossa. Baseline images recorded for 60 s, after which a blood pressure cuff placed 202 
around the forearm was inflated to 220 mm Hg. After 2 min of occlusion, the pressure was 203 
rapidly released to allow reactive hyperemia, with image collection continuing for 5 min post 204 
release. A single, fully trained researcher, who was blinded to the intervention details, 205 
analyzed all image files and peak diameter was defined as the maximum diameter obtained 206 
after the occlusion was released. FMD response was calculated as relative diameter change 207 
from baseline as compared to peak diameter during hyperemia and presented as percentage 208 
change.  209 
 210 
2.5.2. Laser Doppler Imaging 211 
Laser Doppler flowmetry/imaging to measure cutaneous perfusion accompanied by 212 
iontophoresis of acetylcholine and sodium nitroprusside was carried out as previously 213 
described [22] as secondary outcome. Measurements were taken after 30 min of 214 
acclimatization in a supine position in a quiet, temperature controlled room (22 - 24 ºC). The 215 
incremental area under the flux versus time curve for 20 scans was used as a measure of micro 216 
vascular response to acetylcholine (Ach; endothelium dependent vasodilation) and sodium 217 
nitroprusside (SNP; endothelium independent vasodilation). 218 
 219 
2.5.3. Systolic and diastolic blood pressure 220 
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Systolic and diastolic blood pressure measures were performed automatically using an 221 
Omron, MX2 digital upper-arm blood pressure monitor (Omron Electronics Ltd, Milton 222 
Keynes, UK).  Volunteers were previously rested in the supine position for approximately 30 223 
min, during FMD measurement, and required to remain in this position or become semi-224 
recumbent during repeated measures. Blood pressure readings were taken every 2 min until 3 225 
successful readings were obtained, according to consistency. The average of these readings 226 
were calculated in excel and reported as mean and SEM. 227 
 228 
2.6. Biochemical analyses 229 
Blood samples were drawn from volunteers (Figure 1) via an in situ cannula and blood 230 
vacutainer system into EDTA (flavanol metabolite analysis) and sodium heparin 231 
(nitrite/nitrate analysis).  Samples were collected on ice and immediately centrifuged (1700 x 232 
g; 15 min at 4°) and plasma aliquots of 1 ml were frozen at -80° until analysis.  Plasma stored 233 
for metabolite analysis and nitrate/nitrite analysis were treated with ascorbic acid (200 mg/ml; 234 
5 % v/v) and nitrite preservation solution (100 μM N-ethylmaleimide, NEM), respectively.   235 
 236 
2.6.1. Plasma metabolite analysis 237 
Analysis of total plasma (-)-epicatechin metabolites TPEM was as previously 238 
described [23]. Plasma samples (200 μl) were thawed on ice and spiked with internal 239 
standards. After protein precipitation, samples were filtered, washed with 200 μl methanol and 240 
dried at room temperature under a flow of nitrogen.  Finally, the residue was dissolved in 100 241 
μl of 8 % acetonitrile in acidified water. Half of the volume was directly injected into the 242 
ultraperformance liquid chromatography UPLC-ESI-MS/MS system for quantification of total 243 
(-)-epicatechin metabolites which were separated by reversed-phase UPLC using a C18-244 
column Acquity UPLC HSS (2.1 mm x 100 mm, 1.8 μm), (Waters AG, Baden-Dättwil, 245 
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Switzerland) following the chromatographic method described by Actis-Goretta et al. [23]. 246 
Data were collected and processed using Analyst software (AB Sciex Switzerland GmbH, C/o 247 
Applied Biosystems Europe BV, Zug, Switzerland). Each participants' samples were analyzed 248 
within a single assay batch in random sequence. The samples were analyzed blind. 249 
2.6.2. Plasma nitrite and nitrate analysis: 250 
Plasma levels of circulating nitrite and nitrate were individually assessed using an 251 
Eicom NOx Analyzer ENO-30 (San Diego, USA), a dedicated high-performance liquid 252 
chromatography (HPLC) system developed by Eicom Corporation (Japan). This system uses a 253 
post-column diazo coupling reaction (Greiss reaction) combined with HPLC using a NO-PAK 254 
separation column. The followed method was that proposed by Ishibashi et al. [24]. 255 
 256 
Nitrite and nitrate standard stock solutions were prepared in PBS buffer using sodium 257 
nitrite and sodium nitrate salts, respectively. On each day of analysis, a nitrite/nitrate working 258 
standard solution was prepared using the premade stock solutions and methanol. Eight 259 
calibration standards were prepared by series dilution containing nitrite and nitrate in the 260 
following concentrations: 1.6, 0.8, 0.4, 0.2, 0.1, 0.075, 0.05 and 0.025 μM and 100, 50, 25, 261 
12.5, 6.25, 3.125 and 1.5625 μM, respectively.  After deproteinisation of plasma samples with 262 
methanol, 10 μl was injected into the HPLC-system via a programmed autosampler (Waters, 263 
UK).  The binary system phases were solvent A (carrier) and solvent B (reactor) with a flow 264 
rate of 330 μl min-1 and 100 μl min-1, respectively.  The nitrite present is able to react with the 265 
Greiss reagent generating a red diazo compound, and absorbance is quantitatively measured 266 
by spectrophotometric detection at 540 nm.  Furthermore, nitrate passing through the 267 
reduction column was reduced to nitrite prior to undergoing the same diazo coupling reaction. 268 
Calibration standards previously prepared were used for comparison with the peak areas of 269 
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absorption produced by the test plasma samples in order to quantify the nitrite and nitrate 270 
present. 271 
 272 
2.7. Power calculation and Statistical analysis 273 
A power calculation was performed for the primary endpoint measure of change in 274 
FMD response based on statistical limitations associated with this measure in order to 275 
determine an accurate minimum number of volunteers required to power the trial.  The 276 
minimal statistically significant measurable improvement in FMD was set at an absolute 277 
change of 1.5% whilst considering a baseline vasodilation (FMD response) of 6.0 %, based on 278 
previous clinical assumptions that the minimal statistically significant improvement 279 
detectably following drug/nutrient interventions is an absolute change in FMD of 1.5-2% [21]  280 
The sample size was calculated based on a variance of repeated measures of 1.8%, deduced 281 
from the inter-individual variability analysis of data collected in a FMD pilot reproducibility 282 
study. This is consistent with previous, similar clinical trials that have used a standard 283 
deviation of 2.3% [9, 18].  Using a standard deviation of 1.8%, a significance level of 0.05 284 
and a power of 80 % a total of 18 volunteers were required to observe significant within-285 
subject differences between treatments of at least 1.5%. Therefore, assuming a dropout rate of 286 
10% we aimed to recruit 20 volunteers in total. 287 
 288 
All results were expressed as means ± standard error of the mean (SEM), and further 289 
statistically analysed using GraphPad Prism version 5 software (Graphpad Software Inc. San 290 
Diego, CA, USA). Two-factor repeated measures ANOVA was utilized to assess time course 291 
data for study endpoint outcomes in order to estimate intra-individual treatment effects, with 292 
pairwise comparisons corrected using the Bonferroni test during post-hoc analysis. Statistical 293 
significance was assumed if a null hypothesis could be rejected at p = 0.05 values represented 294 
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in figures are as follows: *p = 0.01-0.05, **p = 0.001-0.01, ***p < 0.0001. LDI results were 295 
expressed as area under the cure (AUC) and incremental AUC (iAUC) calculated using the 296 
trapezoidal method.  A correlation analysis was performed using Pearson’s correlation 297 
coefficient to assess relationship between FMD and total plasma (-)-epicatechin metabolites 298 
(TPEM) during the timecourse. 299 
 300 
3. Results 301 
3.1. Baseline characteristics of sample population 302 
The characteristics of the study population are detailed in Table 1.  Baseline 303 
characteristics were calculated and expressed as means ± SEMs and mean values for 304 
parameters were all within the normal range for healthy individuals. The pure (-)-epicatechin 305 
test drinks were well tolerated and no adverse advents were reported in the context of the 306 
study. 307 
 308 
3.2. (-)-Epicatechin induced dose-dependent increases in vascular function 309 
Significant increases in % FMD were observed after ingestion of 0.5 mg kg-1 BW at 2 310 
h (p < 0.01) and similarly at 1 h (p < 0.01) and 2 h (p < 0.001) following ingestion of the 311 
highest dose, 1.0 mg kg-1 BW.  Significant differences in FMD were also identified between 312 
the highest (-)-epicatechin dose (1.0 mg kg-1 BW) and the lowest (-)-epicatechin dose (0.1 mg 313 
kg-1 BW) at 1 h (p < 0.05) and 2 h (p < 0.01) after consumption of the test drinks (Figure 2A).  314 
Peak vasodilation occurred at 2 h after treatments (0.5 and 1.0 mg kg-1 BW), with subsequent 315 
declines in FMD response towards baseline at 4 and 6 h.  FMD response (endothelium-316 
dependent brachial artery vasodilation) increased after ingestion of all 3 pure (-)-epicatechin 317 
test drinks administered to volunteers in a dose-dependent manner between 1 and 2 h (Figure 318 
2B).   The magnitude of increase from baseline (0 h) to 1 h was 1.6  ± 0.3 % following (-)-319 
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epicatechin (1.0 mg kg-1 BW), and at 2 h FMD increased by 1.2 ± 0.3 % and 2.9 ± 0.3 % after 320 
ingestion of 0.5 mg kg-1 and 1.0 mg kg-1 BW (-)-epicatechin, respectively. No significant 321 
changes in FMD were observed at baseline (0 h), 4 h and 6 h and no significant changes in 322 
FMD were observed at any time-point following intake of 0.1 mg kg-1 BW (-)-epicatechin and 323 
the control. Both LDI (Figure 3) and BP (Figure 4) measures were not significantly altered 324 
after consumption of any of the (-)-epicatechin dose intakes compared with baseline or the 325 
control drink. 326 
 327 
3.3. Relationship of FMD to plasma (-)-epicatechin metabolites and NOx 328 
Mean plasma concentrations of epicatechin metabolites ranged from 0.19 to 9.93 μmol L-1 329 
following consumption of pure (-)-epicatechin treatments (excluding control) up to 6 h.  The 330 
time course for the appearance of flavanol metabolites in the circulation paralleled FMD data, 331 
although in all cases peak metabolite concentrations preceded peak FMD (Fig 2A) at 1 h.  332 
Analysis using a 2-factor repeated measures ANOVA indicated significant increases in 333 
plasma flavanol metabolites following ingestion of 0.5 and 1.0 mg kg-1 BW pure (-)-334 
epicatechin at 1 h (p  < 0.001), 2 h (p  < 0.001) and 4 h (p < 0.01 and p < 0.001, respectively) 335 
and additionally at 6 h (p  < 0.01) for 1.0 mg kg-1 BW (-)-epicatechin (Figure 5).  Total 336 
plasma concentrations of (-)-epicatechin metabolites were at or below the limit of detection 337 
(0.01 μmol L-1) for the control at all time points and for the lowest intake at 4 and 6 h.  338 
Analysis using Pearson’s correlation coefficient found positive associations with intake 339 
amount between % FMD response and TPEM at 1 h and 2 h.  At 1 h, coefficients between % 340 
FMD and TPEM were R2 = 0.010, R2 = 0.013 and R2 =0.174, for 0.1, 0.5 and 1.0 mg kg-1 BW 341 
(-)-epicatechin, respectively. At 2 h correlation coefficients with TPEM were  R2 = 0.07 and 342 
R2 = 0.206 for the 0.5 and 1.0 mg kg-1 BW (-)-epicatechin, respectively (Figure 5).  A 2-factor 343 
repeated measures ANOVA found no significant increases in plasma nitrite, nitrate or NOx at 344 
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any timepoint during the crossover intervention comparative to baseline and control measures 345 
(p > 0.05) (Figure 6).   346 
 347 
4. Discussion 348 
Previous works focused on the beneficial vascular effects of cocoa has predominantly 349 
centered on the physiological actions of the total flavanol content [3-10, 19]. However, 350 
although (-)-epicatechin seems to be the main responsible compound for vascular effect, a 351 
direct cause and effect relationships between intake and efficacy are difficult to establish 352 
following the consumption of complex food matrices such as cocoa. Therefore, a proof of 353 
concept study with pure (-)-epicatechin was performed, providing insight, for the first time, 354 
into the dose-dependent effect of its vasoactive benefits post intake and insights into the 355 
circulating metabolites and nitric oxide pool that might mediate such effects. 356 
In response, this acute crossover intervention trial investigating the vascular effects of 357 
pure (-)-epicatechin provided further evidence for the increase vascular function of this 358 
compound, and in particular the impact of FMD % response of the brachial artery. In 359 
agreement with our data, the oral administration of pure (-)-epicatechin in a human 360 
intervention causally linked to the increase of FMD % [18], contrary to other studies which 361 
put to rest the idea that (-)-epicatechin represents a compound with cardiovascular health 362 
benefits [19]. Data shows clear dose-dependent increases in FMD following pure (-)-363 
epicatechin interventions, and specifically at 1 h and 2 h after ingestion of the middle dose 364 
(0.5 mg kg-1 BW) and highest dose (1.0 mg kg-1 BW), where increasing magnitude and 365 
statistical significance was observed, respectively.  However, after conducting post-hoc power 366 
calculations for the lower dose treatment, 0.1 mg kg-1 BW, no significant variations were 367 
observed in comparison with those FMD % values for control treatment. Until now, the 368 
minimum dose of (-)-epicatechin proven to be vascular active was 1 mg kg-1 BW [18]. Our 369 
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results evidence that the ingestion of lower doses, 0.5 mg kg-1 BW, is enough to induce a 370 
physiologically increase in FMD %. Currently, evidence of a significant increase in FMD 371 
with an intervention dose as low as 0.5 mg kg-1 pure (-)-epicatechin BW has not been directly 372 
reported, and therefore provides much needed dose-related insight regarding active and 373 
minimum-active doses capable of inducing acute improvements in FMD, within a healthy 374 
population.  375 
  376 
From baseline mean FMD % reach the maximal change two hours after treatment 377 
ingestion at 0.5 and 1.0 mg kg-1 BW doses which is consistent with the timecourse of total 378 
plasma (-)-epicatechin metabolites (TPEM). This fact suggests that there is an optimal level of 379 
circulating (-)-epicatechin metabolites for driving physiological effect on the endothelium 380 
after two hours of treatment ingestion. Other studies also reported intake-dependent biphasic 381 
improvements in FMD paralleled with appearance of individual phenolic plasma metabolites 382 
following an intervention of flavanol-rich food such as blueberry, cocoa or coffee, showing 383 
the higest level after 2 hours ingestion [18, 25, 26]. (−)-Epicatechin-3′-β-D-glucuronide, (−)-384 
epicatechin-3′-sulfate, and 3′-O-methyl-(−)-epicatechin-5/7-sulfate have been reported as the 385 
major in vivo metabolites present in the bloodstream at 1−3 h after ingestion of cocoa, 386 
chocolate products, or pure compounds [23, 27, 28].  387 
 388 
Potential mechanisms by which such circulating metabolites mediate their vascular effects 389 
have been postulated, and include their potential to inhibit NADPH oxidase, thus affecting 390 
superoxide production and subsequent NO bioavailability at the vascular epithelium [25, 29, 391 
30]. Because of the fact that FMD is mediated by NO, increases in NOS activity are paralleled 392 
by increases in plasma nitroso species. Particularly, our data do not reveal significant 393 
enhancements in plasma nitrite, nitrate or NOx at any timepoint during the crossover 394 
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intervention. However, results emanated from other studies establish a causal link among 395 
parallel measurements of FMD and circulating NO species in conjunction with NOS 396 
inhibition studies after oral ingestión of flavanol which represents a mechanistically strong 397 
experiment framework [9, 18, 31, 32]. 398 
 399 
In conclusion our findings support the notion that (-)-epicatechin is an important mediator 400 
of the cardiovascular effects of flavanols rich food. A clearer picture of dose-dependency of (-401 
)-epicatechin is drawn since our data adds new evidence demonstrating significant activity 402 
from as low as 0.5 mg kg-1 BW (-)-epicatechin, with increasing magnitude and significance 403 
to the highest dose intervened in the trial. Although, data from this acute study cannot be used 404 
to determine the long term effects of repeated consumption of (-)-epicatechin on vascular 405 
function and the study population is limited to healthy young males, findings in the current 406 
paper may provide new avenues to dietary or therapeutic interventions aimed at improving 407 
and maintaining cardiovascular health 408 
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